Cargando…
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)
BACKGROUND: Radiotherapy (RT) following breast-conserving surgery (BCS) is mainly used to decrease the rate of ipsilateral breast tumor recurrence (IBTR) in women with breast ductal carcinoma in situ (DCIS). Recent studies have demonstrated that low-dose tamoxifen significantly reduces IBTR in breas...
Autores principales: | Kuo, Sung-Hsin, Tseng, Ling-Ming, Chen, Shou-Tung, Sagara, Yasuaki, Chang, Yuan-Ching, Yeh, Hsien-Tang, Kuo, Yao-Lung, Hung, Chih-Chiang, Lu, Tzu-Pin, Lee, Yi-Hsuan, Toi, Masakazu, Huang, Chiun-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500726/ https://www.ncbi.nlm.nih.gov/pubmed/37710198 http://dx.doi.org/10.1186/s12885-023-11291-6 |
Ejemplares similares
-
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast
por: Sagara, Yasuaki, et al.
Publicado: (2017) -
Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer
por: Magnoni, Francesca, et al.
Publicado: (2023) -
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
por: Wärnberg, Fredrik, et al.
Publicado: (2021) -
Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022) -
Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?
por: Cserni, Gábor, et al.
Publicado: (2019)